I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of ...
New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL ...
ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code ...
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, H.C. Wainwright reiterated the Buy rating on ImmunityBio, Inc.
Immunitybio Inc ( (IBRX)) has released its Q3 earnings. Here is a breakdown of the information Immunitybio Inc presented to its investors. ImmunityBio, Inc. is a biotechnology company focused on ...
Clarivate plc has unveiled the 2025 Citation Laureates. Widely considered a predictor of the Nobel Prizes, this recognition has highlighted the discovery of biomolecular condensates in chemistry and ...
PRINCETON, N.J.--(BUSINESS WIRE)--Kanvas Biosciences, a full-stack spatial biology company, today announced results from a clinical trial of fecal microbiota transplantation (FMT) and anti-PD-1 ...
LC3-associated phagocytosis (LAP) is a specialized process for degrading dead cells, microbes or other particles. It plays a ...
Techno-Science.net on MSN
🦠 This human protein inherited from bacteria reveals an unknown aspect of our immunity
What if bacteria held the keys to a part of our own immunity? For several years, some scientists have been exploring ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback